Adult T-Cell Leukemia/Lymphoma · line 2 · Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-MOGAMULIZUMAB`

ID	`IND-ATLL-2L-MOGAMULIZUMAB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-ATLL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB. Major UA access barrier — not registered. Always plan as bridge to alloSCT in fit aggressive ATLL.

Used By

Algorithms

ALGO-ATLL-2L - ALGO-ATLL-2L